Gynecology & Obstetrics in India
Get Gynecology & Obstetrics at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Gynecology & Obstetrics in UAE
Gynecology & Obstetrics at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Gynecology & Obstetrics treatment encompasses a broad spectrum of care — from high-risk obstetric management and minimally invasive gynecologic surgery to advanced oncofertility and robotic-assisted procedures — with success rates ranging from 85% to 98% depending on condition complexity. International patients increasingly choose India and the UAE for these treatments, attracted by JCI- and NABH-accredited institutions staffed by fellowship-trained specialists, wait-time-free scheduling, and costs that are dramatically lower than in Western healthcare systems. GAF Healthcare coordinates end-to-end medical journeys to leading hospitals in Mumbai, Delhi, Chennai, Dubai, and Abu Dhabi, ensuring clinical excellence alongside seamless logistical support for patients and their families.
Hospital Stay: 2–7 days (varies by procedure: 2 days for diagnostic laparoscopy or hysteroscopy; 5–7 days for open myomectomy, radical hysterectomy, or high-risk obstetric delivery with NICU support) • Total Stay in Country (Fit-to-Fly): 1–6 weeks (1–2 weeks for minimally invasive procedures such as laparoscopic hysterectomy or operative hysteroscopy; 4–6 weeks for open abdominal surgery, cesarean section with complications, or complex oncologic procedures) • Success Rate: 85–98% (procedure-dependent: laparoscopic myomectomy 95–98% symptom resolution; IVF-related surgical correction 80–88% subsequent conception rates; radical hysterectomy for Stage IB cervical cancer 85–90% 5-year survival)
What Is It?
Gynecology and obstetrics represent two deeply interrelated medical disciplines governing female reproductive health across the entire lifespan. Gynecology addresses structural, hormonal, infectious, and neoplastic disorders of the uterus, ovaries, fallopian tubes, cervix, vagina, and pelvic floor — ranging from endometriosis, uterine fibroids (leiomyomata), polycystic ovarian syndrome (PCOS), and pelvic organ prolapse, to cervical, endometrial, and ovarian malignancies. Obstetrics manages the physiological and pathological aspects of pregnancy, labor, and the puerperium, including high-risk conditions such as gestational diabetes mellitus (GDM), preeclampsia with severe features, placenta previa, intrauterine growth restriction (IUGR), and preterm labor. Both disciplines are profoundly impacted by systemic comorbidities — hypertension, obesity, autoimmune disorders, and thrombophilias — that demand multidisciplinary coordination with endocrinology, maternal-fetal medicine (MFM), oncology, and urology.
The physiological burden of untreated gynecologic conditions is significant. Uterine fibroids affect up to 70% of women by age 50, causing abnormal uterine bleeding (AUB), iron-deficiency anemia, dyspareunia, and subfertility. Endometriosis — present in approximately 10% of reproductive-age women — triggers chronic pelvic pain, progressive adhesion formation, and ovarian endometrioma development, ultimately compromising oocyte quality and implantation potential. Gynecologic malignancies collectively represent the fourth most common cancer group in women globally, with ovarian cancer carrying the highest case-fatality ratio due to late-stage diagnosis. On the obstetric spectrum, preeclampsia complicates 2–8% of pregnancies worldwide and remains a leading cause of maternal and perinatal morbidity, necessitating close surveillance with serial biophysical profiles, uterine artery Doppler indices, and laboratory monitoring of platelet counts, hepatic enzymes, and creatinine.
The contemporary standard of care integrates evidence-based pharmacotherapy with advanced surgical and assisted reproductive technologies. First-line medical management for AUB includes hormonal IUDs (levonorgestrel 52 mg), combined oral contraceptives, GnRH agonists (leuprolide acetate), and the newer GnRH antagonist-based oral regimens (elagolix, relugolix) for fibroid and endometriosis management. Surgical care has transitioned decisively toward minimally invasive approaches: laparoscopic and robotic-assisted hysterectomy, single-incision laparoscopic surgery (SILS), and office-based hysteroscopic procedures (NovaSure endometrial ablation, Myosure tissue removal). Oncologic gynecology increasingly employs sentinel lymph node mapping with indocyanine green (ICG) fluorescence, fertility-sparing trachelectomy for early cervical cancer, HIPEC (hyperthermic intraperitoneal chemotherapy) for advanced ovarian malignancy, and PARP inhibitor maintenance therapy (olaparib, niraparib) for BRCA-mutated ovarian cancer. Indian and UAE centers at the forefront of this field operate da Vinci Xi robotic platforms, high-resolution 4K laparoscopic towers, and integrated operating rooms with intraoperative fluorescence imaging — delivering outcomes equivalent to leading Western academic medical centers.
Candidates
• CANDIDATES FOR GYNECOLOGIC SURGERY:
• Women with symptomatic uterine fibroids (AUB-L per PALM-COEIN classification) causing anemia (hemoglobin <10 g/dL), bulk symptoms, or subfertility, where medical therapy has failed or is contraindicated
• Patients with confirmed endometriosis (rASRM Stage II–IV) refractory to hormonal suppression, or endometrioma >4 cm with ovarian reserve compromise (AMH <1.1 ng/mL, AFC <7)
• Women with abnormal uterine bleeding with endometrial hyperplasia with atypia (WHO 2014 classification) or Stage I endometrial carcinoma seeking fertility-sparing management
• Patients with pelvic organ prolapse (POP-Q Stage III–IV) or genuine stress urinary incontinence (urodynamically confirmed) requiring surgical correction (sacrocolpopexy, mid-urethral sling)
• Women with cervical dysplasia (CIN 2–3, AIS) requiring LEEP/LLETZ, cold-knife conization, or fertility-sparing trachelectomy
• Patients with ovarian masses with high-risk features on IOTA ADNEX modeling or elevated CA-125/HE4 (ROMA score >7.4% premenopausal, >25.3% postmenopausal) requiring surgical staging
• Adolescents or adults with Müllerian anomalies (ASRM Class I–VI) causing hematocolpos, recurrent pregnancy loss, or subfertility
• CANDIDATES FOR HIGH-RISK OBSTETRIC CARE:
• Pregnant women with pre-existing comorbidities: Type 1/2 diabetes (HbA1c >6.5%), chronic hypertension, systemic lupus erythematosus, antiphospholipid syndrome, or inherited thrombophilias (Factor V Leiden, Protein C/S deficiency)
• Patients with prior uterine surgery (myomectomy, classical cesarean) requiring trial of labor after cesarean (TOLAC) risk stratification or planned repeat cesarean
• Pregnancies complicated by placenta previa, placenta accreta spectrum (PAS) disorder, or vasa previa requiring multidisciplinary delivery planning
• Multiple gestations (dichorionic-diamniotic or monochorionic) requiring serial surveillance with discordance assessment and selective fetal reduction counseling
• Patients with recurrent pregnancy loss (≥2 consecutive losses) requiring thrombophilia workup, karyotyping, hysteroscopic uterine evaluation, and immunologic profiling
• REQUIRED DIAGNOSTIC WORKUP (PRE-TRAVEL RECORDS TO ARRANGE):
• Transvaginal ultrasound (TVS) with saline infusion sonohysterography (SIS) for uterine cavity assessment
• MRI pelvis with contrast for fibroid mapping, adenomyosis staging, or endometrioma characterization
• Serum AMH, Day 2–3 FSH/LH/E2, antral follicle count (AFC) for ovarian reserve assessment
• CA-125, HE4, ROMA score, CEA, AFP for adnexal mass evaluation
• Complete blood count, coagulation profile (PT/INR, aPTT), comprehensive metabolic panel, thyroid function (TSH, Free T4)
• Cervical cytology (Pap smear) with reflex HPV genotyping (16/18 plus 12 other high-risk types)
• Obstetric: Serial growth ultrasound with umbilical and uterine artery Doppler indices, fetal echocardiography, non-stress test (NST), biophysical profile (BPP)
• Genetic screening: Cell-free fetal DNA (cfDNA/NIPT), chorionic villus sampling (CVS), or amniocentesis as indicated
• CONTRAINDICATIONS:
• Uncontrolled coagulopathy or thrombocytopenia (<50,000/μL) uncorrected pre-operatively
• Active pelvic inflammatory disease (PID) or uncontrolled sepsis (surgical delay until resolution)
• Hemodynamic instability requiring ICU stabilization prior to elective gynecologic surgery
• Advanced malignancy with WHO performance status ≥3 where surgery offers no survival benefit
• Gestational age <34 weeks for elective cesarean without documented fetal lung maturity or maternal indication
Procedure
MINIMALLY INVASIVE GYNECOLOGIC SURGERY (MIGS):
• Operative Laparoscopy: The cornerstone of modern gynecologic surgery. Multi-port and single-incision laparoscopic approaches (SILS/SPA) are employed for hysterectomy (total laparoscopic hysterectomy, TLH), myomectomy, ovarian cystectomy, salpingectomy, adhesiolysis, and endometriosis excision. Surgeons operate with 4K ultra-HD camera systems and articulating instruments achieving 7-degree-of-freedom movement. Contained power morcellation within FDA-cleared isolation bags (e.g., PneumoLiner) is used where tissue retrieval is required.
• Robotic-Assisted Surgery (da Vinci Xi/SP Platform): Offers 3D stereoscopic visualization at 10× magnification, tremor filtration, and wristed instrument articulation surpassing human wrist range of motion. Preferred for complex procedures: radical hysterectomy (Querleu-Morrow Type B/C), robotic sacrocolpopexy for apical prolapse, nerve-sparing radical hysterectomy with sentinel lymph node (SLN) mapping using ICG fluorescence (FIREFLY imaging). Robotic myomectomy enables precise multilayer uterine reconstruction with suturing equivalent to open technique, critical for subsequent pregnancy integrity.
• Operative Hysteroscopy: Office or OR-based endoscopic procedures for intrauterine pathology — hysteroscopic myomectomy (STEPW classification Type 0–2), endometrial polypectomy, hysteroscopic septoplasty, and endometrial ablation (NovaSure impedance-controlled system, Minerva, ThermaChoice). Resectoscopy with bipolar energy (Versapoint, Karl Storz) enables bloodless tissue removal under continuous flow distension.
• Urogynecology & Pelvic Reconstructive Surgery: Tension-free vaginal tape (TVT-O, ATOMS adjustable sling) for stress urinary incontinence; robot-assisted sacrocolpopexy with lightweight polypropylene mesh for vault prolapse; native tissue repair (uterosacral ligament suspension, McCall culdoplasty) for mesh-averse patients.
ONCOLOGIC GYNECOLOGY (SURGICAL):
• Fertility-Sparing Procedures: Radical vaginal or abdominal trachelectomy (Dargent procedure) with pelvic lymph node dissection for Stage IA2–IB1 cervical cancer; hysteroscopic resection with progestin IUD placement for Grade 1 endometrial cancer/atypical hyperplasia in young women desiring uterine preservation.
• Cytoreductive Surgery + HIPEC: For advanced epithelial ovarian cancer (Stage IIIC–IV), interval debulking surgery (IDS) following 3 cycles of neoadjuvant carboplatin/paclitaxel, followed by HIPEC (cisplatin 75 mg/m² at 42°C for 90 minutes) at the time of surgery, has demonstrated a 3.5-month overall survival advantage in the OVHIPEC-1 trial. Leading Indian and UAE centers (Tata Memorial Mumbai, Apollo Hospitals, Cleveland Clinic Abu Dhabi) offer this as standard care.
• Sentinel Lymph Node Mapping: ICG-based SLN biopsy replacing systematic pelvic lymphadenectomy in endometrial cancer staging (Stage I–II), reducing lymphedema incidence from ~25% to <5% while maintaining 97% sensitivity for nodal metastasis detection.
OBSTETRIC PROCEDURES:
• High-Risk Obstetric Surveillance: Serial cervical length measurement (transvaginal, ≤25 mm triggering progesterone supplementation), uterine artery Doppler pulsatility index monitoring, and maternal-fetal medicine (MFM) specialist-led care coordination.
• Placenta Accreta Spectrum (PAS) Management: Multidisciplinary delivery planning for accreta/increta/percreta involving obstetric surgery, interventional radiology (internal iliac artery balloon occlusion or embolization), urology, and blood bank (massive transfusion protocol activation). Cesarean hysterectomy with preoperative ureteral stenting is the definitive management.
• Fetal Intervention: In-utero procedures including amniocentesis, fetal blood sampling (cordocentesis), fetoscopic laser photocoagulation of placental anastomoses for twin-to-twin transfusion syndrome (TTTS Quintero Stage II–IV), and fetal shunting procedures.
PHARMACOLOGIC & ASSISTED REPRODUCTION ADJUNCTS:
• GnRH Antagonists (Elagolix/Relugolix): Oral non-peptide GnRH receptor antagonists for preoperative fibroid volume reduction and endometriosis pain management, with add-back estradiol/norethindrone to mitigate hypoestrogenic side effects.
• PARP Inhibitors (Olaparib, Niraparib, Rucaparib): Maintenance therapy post-platinum-based chemotherapy in BRCA1/2-mutated or HRD-positive ovarian cancer — extending progression-free survival by 18–36 months in Phase III trials (SOLO-1, PRIMA).
• Anti-VEGF Therapy (Bevacizumab): Combined with carboplatin/paclitaxel for Stage IV or recurrent ovarian cancer; also used in PAS management protocols to reduce tumor-like vascular invasion.
Cost of Gynecology & Obstetrics: India vs. UAE
The cost of gynecology and obstetrics treatment varies significantly based on the specific procedure, hospital tier, and destination country. India offers world-class surgical outcomes at 40–65% lower cost than the UAE, while the UAE — particularly Dubai and Abu Dhabi — provides premium infrastructure, European-standard hotel-style rooms, and geographical convenience for patients from the Middle East, Africa, and Europe. Both destinations offer JCI-accredited institutions with internationally trained specialists. The estimates below cover the primary procedure, standard anesthesia, hospital stay, nursing care, and routine medications; adjuvant chemotherapy, extended NICU stays, blood products, and implantable devices may be billed separately.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $1,200 – $9,500 | ~57% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $3,000 – $22,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PRE-TRAVEL PHASE (4–8 WEEKS BEFORE DEPARTURE):
• GAF Healthcare case manager reviews all prior medical records, imaging (DICOM files preferred), pathology reports, and operative notes
• Remote teleconsultation with the treating gynecologist or MFM specialist in India or the UAE is arranged — typically within 72 hours of inquiry
• Specialist issues a detailed treatment plan, procedure recommendation, and cost estimate
• Pre-operative blood work and imaging protocols are communicated so the patient can complete investigations locally before travel, minimizing in-country workup time
• Visa arrangements initiated: e-Medical Visa (India) or UAE entry visa assistance coordinated by GAF Healthcare
ARRIVAL & PRE-OPERATIVE ASSESSMENT (DAYS 1–2):
• Airport pickup by GAF Healthcare's dedicated transport service; accommodation arranged within 5–10 minutes of the hospital
• Day 1: Hospital registration, pre-admission assessment clinic — repeat TVS or pelvic MRI review, anesthesia fitness evaluation (ASA classification, airway assessment, cardiac/pulmonary clearance if indicated), and updated blood work (CBC, coagulation, metabolic panel, blood group & crossmatch)
• Day 2: Consent process with surgeon; bowel prep if indicated (mechanical bowel prep for procedures involving rectovaginal dissection or colonic resection in advanced endometriosis/ovarian cancer); thromboprophylaxis initiated (LMWH dosing per ACOG/RCOG protocol based on VTE risk stratification using Caprini or modified Sheffield score)
• Gynecologic oncology cases: Tumor board (MDT) review confirmed; pre-operative marking and stoma counseling if applicable
PROCEDURE DAY:
• General or spinal/epidural anesthesia administered by fellowship-trained obstetric/gynecologic anesthesiologist
• Laparoscopic/robotic cases: Pneumoperitoneum established at 12–15 mmHg CO₂; uterine manipulator placed (Koh-Efficient or RUMI II); procedure performed with real-time fluorescence imaging where SLN mapping is indicated
• Operative hysteroscopy cases: Distension media management (isotonic saline for bipolar; 1.5% glycine for monopolar) with continuous fluid deficit monitoring (maximum allowable deficit 2,500 mL normal saline / 1,000 mL hypotonic)
• Open cases (radical hysterectomy, cytoreductive surgery + HIPEC): 3–5 hour operative time; intraoperative cell salvage, normothermic or hypothermic perfusion protocols, and real-time hemodynamic monitoring with arterial line and central venous access
• Obstetric delivery (planned cesarean or high-risk vaginal birth): Neonatology team on standby; NICU admission pathway pre-arranged
IMMEDIATE POST-OPERATIVE RECOVERY (DAYS 1–3 POST-OP):
• Laparoscopic/hysteroscopic cases: Ambulation within 6 hours; clear liquids same day; urinary catheter removed Day 1; discharge Day 1–2
• Robotic/open cases: Epidural analgesia or multimodal pain protocol (IV acetaminophen + ketorolac + dexamethasone; avoid opioid-heavy regimens); incentive spirometry and chest physiotherapy initiated Day 0; drain output monitored (Jackson-Pratt or Blake drain); nasogastric tube removed when bowel sounds return (typically 24–48 hours)
• HIPEC cases: ICU monitoring for 24–48 hours; nephrotoxicity surveillance (serum creatinine, cystatin C); neutropenia monitoring if intraoperative cisplatin used
• Thromboprophylaxis: TED stockings and pneumatic compression devices intraoperatively and until full ambulation; LMWH continued 28 days for oncology cases per ACOG/ASCO 2023 guidelines
HOSPITAL DISCHARGE MILESTONES:
• Tolerating solid diet, passing flatus/bowel movement, pain controlled on oral analgesia, independent ambulation, afebrile for >24 hours
• Discharge summary, histopathology tracking reference, and outpatient follow-up appointment issued
• Laparoscopic/hysteroscopic cases: discharge Day 1–2; open/radical cases: Day 5–7; high-risk obstetrics: Day 3–5 post-delivery
IN-COUNTRY RECOVERY (HOTEL/SERVICED APARTMENT PHASE):
• Weeks 1–2: Light activity only; wound inspection at Day 7 by GAF-coordinated local physician; staple/suture removal; drain removal if applicable
• Week 2–4 (open cases): Gradual return to walking; dietary protein optimization; pelvic floor physiotherapy initiated at Week 3–4 for prolapse/urinary cases
• Histopathology results typically available within 5–7 business days; GAF Healthcare facilitates teleconsultation with pathologist and treating surgeon to discuss results and adjuvant therapy planning
FIT-TO-FLY CLEARANCE:
• Laparoscopic/hysteroscopic procedures: 10–14 days post-procedure; surgeon signs Fit-to-Fly certificate; compression stockings mandatory for flight >4 hours; LMWH on day of flight if >4-hour journey
• Open abdominal/radical procedures: 4–6 weeks; confirmed by clinical review and absence of wound complication, DVT (if symptomatic, duplex Doppler performed)
• Post-cesarean (uncomplicated): 3–4 weeks; post-cesarean with complications (PAS, hemorrhage): 5–6 weeks with hematology clearance
• Oncology cases starting adjuvant chemotherapy: GAF Healthcare assists in arranging initiation of first cycle in India/UAE before departure, with referral letter to home oncologist for continuation
Risks & Considerations
Gynecologic and obstetric procedures carry procedure-specific risks that patients must understand and that GAF Healthcare's partner hospitals actively mitigate through standardized protocols. For laparoscopic and robotic surgery, risks include inadvertent cystotomy (bladder injury, incidence 0.3–1%), ureteral injury (0.1–0.5%), bowel injury (0.1–0.4%), and port-site hernia (<1% with 10 mm trocar closure). Conversion to open laparotomy occurs in 1–3% of cases due to dense adhesions or hemorrhage. Venous thromboembolism (DVT/PE) represents the most critical preventable post-operative risk, with incidence of 0.3–0.5% for benign procedures rising to 3–5% for gynecologic oncology cases without prophylaxis — mitigated by extended LMWH thromboprophylaxis (28 days post-cancer surgery per ACOG/ASCO guidelines). Hysteroscopic procedures carry risk of fluid overload and dilutional hyponatremia if fluid deficit monitoring protocols are breached; this risk is eliminated with modern bipolar energy systems using isotonic distension media. For endometrial ablation, a 5–10% long-term failure rate (continued bleeding) requiring subsequent hysterectomy must be counseled. HIPEC-specific risks include nephrotoxicity (cisplatin-induced acute kidney injury in 8–12%), bone marrow suppression, prolonged ileus (10–15%), and anastomotic leak if bowel resection was performed (3–6%). Obstetric risks in high-risk pregnancy management include preterm delivery despite intervention (cervical cerclage failure in 15–20% of high-risk cervixes), fetal distress requiring emergency cesarean, and postpartum hemorrhage (incidence 5–8% of all deliveries, rising to 30–40% in PAS cases) — managed with pre-positioned interventional radiology support and massive transfusion protocols. All GAF Healthcare partner hospitals maintain 24/7 blood banking with cell salvage technology, critical care backup, and morbidity review committees that benchmark complication rates against ACOG and ESGO international standards.
Top Hospitals for Gynecology & Obstetrics
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Kings College Hospital Dubai
Dubai, UAE
Aster Hospital Dubai
Dubai, UAE
Top Doctors for Gynecology & Obstetrics
Internationally trained specialists in Gynecology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Anuradha Khurana
MBBS, DGO (Diploma in Obstetrics & Gynaecology), PG in High Risk Pregnancy and Infertility
Gynecologist & Obstetrics Specialist
Artemis Hospital, New Delhi, India
20+ Yearsof experience
Dr. Anuradha Khurana is a Senior Consultant in Obstetrics and Gynecology at Artemis Hospital, Delhi, with over two decades of hands-on experience in women's health. She is particularly well regarded for her work in high-risk pregnancy management, uterine conditions like fibroids and endometriosis, and complex gynecological surgeries. Patients and families consistently describe her as someone who takes the time to truly listen — and to explain things in a… Read more
Dr. Deepti Gupta
MBBS, MS (Obstetrics & Gynaecology)
Gynecologist & Obstetrics Specialist
Fortis Hospital, Shalimar Bagh, New Delhi, India
13+ Yearsof experience
Dr. Deepti Gupta is a Consultant in Obstetrics and Gynecology based at Fortis Hospital, Shalimar Bagh, in New Delhi, with over 13 years of dedicated clinical experience. She is known for her thoughtful management of high-risk pregnancies, recurrent miscarriages, infertility, and the full range of menopausal health concerns. Patients and families consistently describe her as someone who listens carefully and explains clearly — a quality that makes a real… Read more
Dr. Renu Raina Sehgal
MBBS, MD — Obstetrics & Gynaecology, DNB — Diplomate of National Board of Medical Sciences, Fellowship — Advanced Gynaecological Laparoscopy, FMAS — Fellow, Association of Minimal Access Surgeons of India, DRS — Certified Da Vinci Robotic Console Surgeon
Gynecologist & Obstetrics Specialist
Artemis Hospital, Gurgaon, India
27+ Yearsof experience
Dr. Renu Raina Sehgal is a highly respected Obstetrician and Gynecologist with over 27 years of clinical experience. She currently heads the Department of Obstetrics & Gynaecology at Artemis Hospital, Gurgaon — one of India's leading multispecialty hospitals. Over the course of her career, she has built a strong reputation for managing complex gynecological conditions and high-risk pregnancies with skill, steadiness, and genuine care for her patients. Dr.… Read more
Dr. Sohani Verma
MBBS, MS (Obstetrics & Gynecology), Fellowship – Reproductive Medicine & Gynecological Surgery
Gynecologist & Obstetrics Specialist
Indraprastha Apollo Hospital, New Delhi, India
35+ Yearsof experience
Dr. Sohani Verma is one of Delhi's most trusted gynecologists, with over 35 years of dedicated practice in women's health. Based at Indraprastha Apollo Hospital in South Delhi, she specializes in obstetrics, gynecological surgery, and fertility care. Patients across India — and from abroad — seek her out for her calm, thorough approach to some of the most sensitive health journeys a woman can face. Dr. Verma completed her MBBS and then pursued a… Read more
Dr. Seema Manuja
Diploma in Advanced Laparoscopic Surgery, MRCOG Part I, MD (Obstetrics & Gynaecology), MBBS
Gynaecologist & Obstetrics Specialist
Sarvodaya Hospital, Faridabad, India
30+ Yearsof experience
Dr. Seema Manuja is one of Delhi NCR's most experienced gynaecologists, currently serving as Director of Gynaecology at Sarvodaya Hospital in Faridabad. With more than 30 years of hands-on clinical practice, she has built a reputation for combining advanced surgical skill with genuinely compassionate care. Her areas of focus include minimally invasive gynaecological surgery, infertility management, recurrent pregnancy loss, high-risk pregnancy, and the… Read more
Frequently Asked Questions — Gynecology & Obstetrics
Costs vary significantly by procedure complexity. In India, gynecologic and obstetric treatments at JCI- and NABH-accredited hospitals typically range from $1,200 to $9,500 USD. This covers procedures from operative hysteroscopy and laparoscopic myomectomy at the lower end (~$1,200–$2,500) to radical hysterectomy with sentinel lymph node mapping (~$4,000–$6,000) and cytoreductive surgery with HIPEC for advanced ovarian cancer (~$7,000–$9,500). In the UAE (Dubai and Abu Dhabi), costs at JCI- and DHA-accredited centers range from $3,000 to $22,000 USD for comparable procedures — reflecting higher infrastructure, hospitality standards, and operating costs. For example, laparoscopic hysterectomy costs approximately $2,500–$4,000 in India versus $6,000–$10,000 in the UAE; robotic-assisted radical hysterectomy ranges from $5,500–$8,000 in India versus $12,000–$18,000 in the UAE. High-risk obstetric care with MFM specialist involvement and NICU support ranges from $3,000–$7,000 in India and $8,000–$20,000+ in the UAE. India is typically 40–65% more affordable, while the UAE offers advantages of geographic proximity for Middle Eastern and African patients and premium hotel-standard private rooms. GAF Healthcare provides detailed, itemized cost estimates for your specific procedure prior to any commitment.
Fit-to-fly timelines depend critically on the specific procedure performed. For minimally invasive procedures — laparoscopic or robotic hysterectomy, laparoscopic myomectomy, operative hysteroscopy, or diagnostic laparoscopy — most patients receive fit-to-fly clearance after 10–14 days in-country. This accounts for 1–2 days of hospital stay and 8–12 days of post-discharge in-hotel recovery with a clinical wound review at Day 7. For open abdominal procedures — open myomectomy, radical abdominal hysterectomy, cytoreductive surgery, or abdominal sacrocolpopexy — 4–6 weeks in-country is required to ensure wound healing, bowel function restoration, and absence of early complications such as wound dehiscence or lymphocyst formation. For uncomplicated planned cesarean section, fit-to-fly clearance is typically granted at 3–4 weeks postpartum; for complex cases involving placenta accreta spectrum, significant hemorrhage, or surgical complications, 5–6 weeks is standard with hematology sign-off. All patients traveling for more than 4 hours must wear graduated compression stockings (Class 2, 18–24 mmHg) and receive a single prophylactic dose of low molecular weight heparin (LMWH) on the day of the flight per RCOG/ACOG thromboprophylaxis guidelines. GAF Healthcare's treating surgeons issue a formal Fit-to-Fly Certificate upon clearance, which most airlines and travel insurance providers require.
Success rates in gynecology and obstetrics are procedure-specific and are benchmarked against international ACOG, ESGO, and FIGO standards at all GAF Healthcare partner institutions. For laparoscopic myomectomy, symptom resolution rates (cessation of abnormal bleeding, pain relief) exceed 92–95%, with a fibroid recurrence rate of approximately 15–20% at 5 years, comparable to leading centers in the US and UK. For laparoscopic and robotic-assisted hysterectomy for benign disease, the complication rate at our partner hospitals is under 3%, with a conversion-to-open rate of less than 2%. In gynecologic oncology, Stage IB1–IB2 cervical cancer treated with radical hysterectomy and pelvic lymph node dissection achieves a 5-year disease-free survival of 85–90%; Stage I–II endometrial cancer treated with robotic staging surgery achieves 5-year survival exceeding 90%. For advanced ovarian cancer (Stage IIIC) treated with maximal cytoreductive surgery (R0 resection) plus HIPEC followed by adjuvant carboplatin/paclitaxel and PARP inhibitor maintenance, progression-free survival has improved to 36–48 months in BRCA-mutated patients. For high-risk obstetric cases managed by fellowship-trained Maternal-Fetal Medicine specialists, maternal complication rates are maintained below 2% for conditions including preeclampsia with severe features and placenta accreta spectrum — outcomes consistent with Level III perinatal centers in North America. GAF Healthcare selects only hospitals that publish their surgical volumes, complication rates, and oncologic outcomes for internal quality review, ensuring patients access verified, outcome-driven centers.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive, medically informed logistical coordination for every international patient traveling for gynecology and obstetrics care — eliminating the administrative burden so patients can focus entirely on treatment and recovery.
VISA ASSISTANCE — INDIA: GAF Healthcare facilitates the e-Medical Visa (e-MV) application for India, which permits a 60-day stay (extendable) and allows one accompanying attendant on a Medical Attendant Visa (e-MAtV). Our case managers provide the hospital letter, treatment confirmation, and cost estimate documents required by the Indian Consulate, with typical visa approval within 3–5 business days of application submission.
VISA ASSISTANCE — UAE: Most nationalities enjoy visa-on-arrival or 30–90-day visa-free access to the UAE. For nationalities requiring prior visa approval, GAF Healthcare coordinates with our DHA-accredited hospital partners in Dubai and Abu Dhabi to issue official invitation letters enabling medical visa processing through the UAE embassy. The process typically takes 5–7 business days.
AIRPORT TRANSFERS & GROUND LOGISTICS: Private, medically equipped vehicle transfers are arranged for all arrival and discharge journeys. For post-cesarean or post-laparotomy patients, vehicles with reclinable seating and sufficient space for comfortable positioning are specifically reserved. Wheelchair assistance and porter services are pre-requested at both the airport and hospital.
DEDICATED PATIENT COORDINATORS & TRANSLATORS: Each patient is assigned a bilingual GAF Healthcare Patient Relationship Manager (PRM) who is available via WhatsApp/phone from pre-arrival through post-discharge follow-up. For patients whose primary language is Arabic, Russian, French, or other languages, professional medical interpreters are arranged for all clinical consultations, consent discussions, and discharge briefings — ensuring no clinical communication gap.
ACCOMMODATION FOR PATIENT & ATTENDANT: GAF Healthcare has pre-negotiated rates at serviced apartments and hotel suites located within 500 meters to 2 km of our partner hospitals. Options range from budget-friendly ($40–70/night, India) to premium ($120–250/night, UAE), all with housekeeping, Wi-Fi, and access to in-room meal delivery services aligned with post-operative dietary restrictions (low-sodium, high-protein, lactation-appropriate for postpartum patients). For attendants accompanying obstetric patients requiring extended NICU stays, monthly apartment leases are arranged at reduced rates.
POST-DISCHARGE MEDICAL FOLLOW-UP: GAF Healthcare coordinates all post-discharge teleconsultation appointments, ensures histopathology and discharge documents are translated and formatted for the patient's home country oncologist or obstetrician, and tracks fit-to-fly clearance milestones. A 24/7 medical helpline is available for urgent clinical questions during the in-country recovery period.
CONTINUITY OF CARE: For oncology patients requiring adjuvant chemotherapy or targeted therapy initiation, our team coordinates with home-country oncologists and provides comprehensive treatment summaries, chemotherapy protocols, and BRCA/molecular testing reports in internationally recognized formats.